Rotarex血栓清除术联合药物涂层球囊治疗股腘动脉支架内再狭窄:3年随访结果分析

doi:10.3969/j.issn.1006-7795.2021.05.022

摘要/Abstract

摘要： 目的评估Rotarex血栓清除术联合药物涂层球囊(drug-coated balloon, DCB)治疗股腘动脉支架内再狭窄(femoropopliteal artery in-stent restenosis, FP-ISR)的有效性和安全性。方法对2016年6月至2017年7月间,接受Rotarex血栓清除术联合DCB治疗的32例FP-ISR患者,进行3年随访。研究的主要终点为术后3年的原发通畅率,免于临床驱动的靶病变再干预率(clinically-driven target lesion revascularization, CD-TLR)。次要终点包括不良事件发生率、截肢率及病死率。患者的术后功能恢复情况由步行障碍调查问卷(Walking Impairment Questionnaire, WIQ)评估。结果所有32例患者均获得了技术成功和手术成功,其中27例(84.4%)患者完成了3年的随访。术前平均踝肱指数(ankle brachial index, ABI)为0.45±0.14,3年时为0.81±0.10(P<0.05);术前WIQ评分为30.45±21.14,3年时为51.32±27.92(P<0.05)。Kaplan-Meier生存曲线结果显示,随访3年,原发通畅率为81.5%,免于CD-TLR为85.2%。结论 Rotarex血栓清除术联合DCB治疗FP-ISR是安全有效的,其中长期结果令人满意。

关键词: 股腘动脉病变, 支架再狭窄, Rotarex血栓清除术, 药物涂层球囊

Abstract: Objective To evaluate the effectiveness and safety of Rotarex thrombectomy combined with drug-coated balloon(DCB) for treatment of femoropopliteal artery in-stent restenosis(FP-ISR). Methods From June 2016 to July 2017, 32 FP ISR patients received Rotarex thrombectomy combined with DCB, which were followed up for 3 years. The primary endpoint was primary patency of the target lesion and freedom from clinically-driven target lesion revascularization (CD-TLR) at 3 years. The secondary endpoint was the rate of major adverse limb events (MALE), amputation and mortality. The primary functional endpoint was assessed by Walking Impairment Questionnaire (WIQ). Results Technical and procedural success was achieved in all 32 patients, 27(84.4%) patients completed 3 years follow-up. Mean ABI was 0.45±0.14 at baseline and 0.81±0.10 at 3 years (P<0.05). The WIQ score was 30.45±21.14 at baseline and 51.32±27.92 at 3 years (P<0.05). The Kaplan-Meier estimate of the primary patency rate at 3 years was 81.5%, freedom from CD-TLR rate at 3 years was 85.2%. Conclusion Rotarex thrombectomy combined with DCB for treatment of FP ISR is safe and effective, the medium and long-term results are satisfactory.

Key words: femoropopliteal artery disease, in-stent restenosis, Rotarex thrombectomy, drug-coated balloon

中图分类号:

R654.4

廖传军, 宋盛晗, 张望德. Rotarex血栓清除术联合药物涂层球囊治疗股腘动脉支架内再狭窄:3年随访结果分析[J]. 首都医科大学学报, 2021, 42(5): 836-840.

Liao Chuanjun, Song Shenghan, Zhang Wangde. Rotarex thrombectomy combined with drug-coated balloon for femoropopliteal artery in-stent restenosis: 3 years follow up results[J]. Journal of Capital Medical University, 2021, 42(5): 836-840.

参考文献

[1] Levin S R, Arinze N, Siracuse J J. Lower extremity critical limb ischemia: A review of clinical features and management[J]. Trends Cardiovasc Med, 2020, 30(3):125-130.
[2] Rooke T W, Hirsch A T, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2011, 58(19): 2020-2045.
[3] Jaff M R, White C J, Hiatt W R, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II): the TASC Steering Comittee[J]. Ann Vasc Dis,2015,8(4):343-357.
[4] Dohi T, Iida O, Soga Y, et al. Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions[J]. J Vasc Surg,2014,59(4):1009-1015.
[5] Shishehbor M H. Endovascular treatment of femoropopliteal lesions: so many options, little consensus[J]. J Am Coll Cardiol,2015,66(21):2339-2342.
[6] Kim W, Choi D. Treatment of femoropopliteal artery instent restenosis[J]. Korean Circ J, 2018,48(3):191-197.
[7] Krankenberg H, Tübler T, Ingwersen M, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized Femoral Artery In-stent Restenosis (FAIR) trial[J]. Circulation,2015,132(23):2230-2236.
[8] Kinstner C M, Lammer J, Willfort-Ehringer A, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial[J]. JACC Cardiovasc Interv,2016,9(13):1386-1392.
[9] Stabile E, Virga V, Salemme L, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis[J]. J Am Coll Cardiol,2012,60(18):1739-1742.
[10]Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study[J]. J Endovasc Ther, 2014,21(1):1-8.
[11]Virga V, Stabile E, Biamino G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up[J]. JACC Cardiovasc Interv,2014,7(4):411-415.
[12]Dippel E J, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITEISR trial (EXCImer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). JACC Cardiovasc Interv,2015,8(1 pt A):92-101.
[13]Schmidt A, Zeller T, Sievert H, et al. Photo ablation using the turbo-booster and excimer laser for in-stent restenosis treatment: twelve-month results from the PATENT study[J]. J Endovasc Ther, 2014,21(1):52-60.
[14]Liao C J, Song S H, Li T, et al. Combination of rotarex thrombectomy and drug-coated balloon for the treatment of femoropopliteal artery in-stent restenosis[J]. Ann Vasc Surg, 2019, 60:301-307.
[15]Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coll Cardiol,2012,59(1):16-23.
[16]Qato K, Conway A M, Mondry L, et al. Management of isolated femoropopliteal in-stent restenosis[J]. J Vasc Surg, 2018,68(3):807-810.
[17]Ho K J, Owens C D. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis[J]. J Vasc Surg, 2017,65(2):545-557.
[18]Indolfi C, Stabile E, Perrino C, et al. Mechanisms of restenosis after angioplasty and approach to therapy[J]. Int J Mol Med, 1998, 2(2):143-148.
[19]Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study[J]. J Endovasc Ther, 2016,23(1):52-57.
[20]Murata N, Takahara M, Soga Y, et al. Drug-eluting stent vs percutaneous transluminal angioplasty for treatment of femoropopliteal in-stent restenosis: results from a retrospective 1-year multicenter study[J]. J Endovasc Ther,2016,23(4):642-647.
[21]Mehrotra S, Paramasivam G, Mishra S. Paclitaxel-coated balloon for femoropoplitral artery disease [J]. Curr Cardiol REP, 2017, 19(2): 10.